NCT02112578View on ClinicalTrials.gov

Non Inferiority of Meclin® (Meclizine Chlorhydrate) Versus Dramin® (Dimenhydrinate) in Control of Acute Vertigo Symptoms From Peripheral Origin

PHASE3CompletedINTERVENTIONAL
Enrollment

292

Participants

Timeline

Start Date

November 1, 2016

Primary Completion Date

April 1, 2017

Study Completion Date

December 1, 2017

Conditions
Vertigo, Peripheral
Interventions
DRUG

Meclizine

25 mg, 3 times per day up to 30 days

DRUG

Dimenhydrinate

50 mg, 3 times per day up to 30 days

Trial Locations (7)

12243280

ISPEM, São José dos Campos

18040425

Clinica de Alergia MarttiAntila, Sorocaba

Unknown

Clinilive, Maringá

Irmandade da Santa Casa de Misericórdia de São Paulo, São Paulo

06454010

Alergoalpha, Barueri

09080110

Pesquisare Saude S/S Ltda, Santo André

04063001

CCBR SP, São Paulo

Sponsors
All Listed Sponsors
lead

Apsen Farmaceutica S.A.

INDUSTRY